Morrison Foerster advised Eton Pharmaceuticals (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, on in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas (“Pierre Fabre”). HEMANGEOL is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.
Infantile hemangiomas are non-cancerous vascular tumors which typically appear in the first days or weeks of a newborn’s life. It is estimated that approximately 5,000-10,000 infants are treated with HEMANGEOL annually in the United States.
The transaction is expected to be accretive to 2026 earnings and will be financed with the company’s cash on hand. Pierre Fabre will continue commercializing HEMANGEOL globally, and in the U.S. until April 30. Effective May 1, Eton will commercialize HEMANGEOL in the U.S.
The MoFo team advising Eton Pharmaceuticals was led by technology transactions and life sciences transactions + licensing partner Matt Ferry with associates Sophie Zander and Jessica Kwok and patent partner Lisa Silverman.
Read the press release.
